Genferon® Light (Genferon Lite)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Similar drugsTo uncover
Dosage form: & nbspnasal drops
Composition:

1 ml of the solution contains:

active ingredients: interferon alfa-2b human recombinant * 10,000 ME, taurine 0.80 mg;

Excipients: disodium edetate dihydrate 0.02 mg, glycerol 7.00 mg, dextran 35-45 thousand 2.4 mg, polysorbate 80 1.0 mg, sodium chloride 0.8 mg, potassium chloride 0 , 02 mg, sodium hydrophosphate - 0.115 mg, potassium dihydrogen phosphate - 0.02 mg, water for injection - up to 1 ml.

* In the substance of the substance "Interferon alfa-2b human recombinant (rchIFN-α2b) "includes auxiliary substances: sodium chloride, sodium acetate trihydrate, acetic acid icy, water for injection.

Description:Transparent colorless or light yellow liquid.
Pharmacotherapeutic group:Immunomodulating agent
ATX: & nbsp
  • Interferon alfa-2b
    • Pharmacodynamics:

    The drug Genferon® Light, nasal drops, has antiviral, immunomodulatory, anti-inflammatory, antiproliferative, antibacterial action, has local regenerating, membrane-stabilizing and antioxidant properties. Interferon alfa blocks the multiplication of viruses at the stage of synthesis of specific proteins and prevents the infection of uninfected cells of the nasal mucosa, which is the site of invasion of the pathogens and the primary focus of inflammation in respiratory infections.Immunomodulatory effect is manifested by intensification of cell-mediated immune system reactions, which increases the effectiveness of the immune response against foreign agents. This is achieved through activation Cd8+ T-killers, NK(natural killer cells), enhancing B-cell differentiation and production of antibodies, activation of the monocyte-macrophage system and phagocytosis, as well as increasing the expression of the molecules of the main histocompatibility complex of the first type, which increases the probability of recognition of infected cells by the cells of the immune system. Activation under the influence of interferon leukocytes contained in all layers of the mucous membrane, ensures their active participation in the elimination of pathological foci; in addition, due to the influence of interferon, the production of secretory immunoglobulin A is restored. The antibacterial effect is mediated by immune system reactions, enhanced by interferon.

    Taurine, which is part of the drug, normalizes metabolic processes in tissues, promotes regeneration and faster recovery of the mucous membrane of the nasal cavity, damaged by the pathological process.

    Pharmacokinetics:

    With intranasal application, the preparation Genferon® Light, nasal drops, creates a high concentration of interferon in the focus of infection and has a pronounced local antiviral and immunostimulating effect. Systemic absorption of the drug is negligible, with intranasal administration of human interferon recombinant alpha-2b in a small amount determined in the lung tissue and blood. In the body, biotransformation occurs predominantly in kidneys with a half-life (T1/2) 5.1 h. A small amount of the drug falling into the systemic circulation, has a systemic immunomodulatory effect.

    Indications:

    Treatment of influenza and other acute respiratory viral infections in children aged from 29 days to 14 years.

    Contraindications:

    - Hypersensitivity to interferon alpha-2b or other components of the drug.

    - Newborns from 0 to 28 days (due to lack of clinical data).

    Pregnancy and lactation:

    It is not used because the drug is indicated for use in children aged from 29 days to 14 years.

    Dosing and Administration:

    At the first signs of the disease, Genferon® light is buried in the nose for 5 days.

    Children from 29 days to 11 months 29 days - 1 drop in each nasal passage 5 times a day (single dose 1,000 ME, daily dose 5 000 ME).

    Children from 1 to 3 years old - 2 drops in each nasal passage 3-4 times a day (single dose 2 000 ME, daily dose 6 000 - 8 000 ME).

    Children from 3 to 14 years - 2 drops in each nasal passage 4-5 times a day (single dose 2 000 ME, daily dose of 8 000 - 10 000 ME).

    Side effects:

    Possible local allergic reactions (burning sensation, itching). These phenomena are reversible and disappear on their own within 72 hours after discontinuation of the drug. Continuation of treatment is possible only after consulting a doctor.

    Overdose:

    Cases of overdose of the drug Genferon® Light have not been registered to date.

    Interaction:

    It is not recommended simultaneous use of intranasal vasoconstrictors, as this causes additional dryness of the mucous membrane of the nasal cavity.

    Special instructions:

    After instillation it is recommended to massage the wings of the nose with your fingers for several minutes to distribute the drug evenly in the nasal cavity.

    Effect on the ability to drive transp. cf. and fur:

    Effect of the drug Genferon® Light on the performance of potentially hazardous activities,requiring special attention and quick reactions (control of vehicles, machinery, etc.), has not been studied.

    Form release / dosage:

    Nasal drops 10 000 ME / ml + 0.8 mg / ml.

    Packaging:

    For 10 ml in bottles of dark glass, hermetically sealed with stoppers, with the rolling of aluminum caps. Each label is labeled. For 1 bottle complete with 1 nozzle-dropper, along with instructions for use in a pack of cardboard.

    For 10 ml in bottles of dark glass, hermetically ukuporennye nozzles, droppers. Each label is labeled. 1 bottle with instructions for use in a pack of cardboard.

    Storage conditions:

    In a dry, protected from light place at a temperature of 2 to 8 ° C.

    Within the indicated period of validity papatients may store the drug after opening for 7 weeks at a temperature of 2 to 8 ° C.

    Keep out of the reach of children.

    Shelf life:

    2 years.

    Do not use after the expiration date stated on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:LP-002309
    Date of registration:25.11.2013 / 06.05.2014
    Expiration Date:25.11.2018
    The owner of the registration certificate:BIOCAD, CJSC BIOCAD, CJSC Russia
    Manufacturer: & nbsp
    Information update date: & nbsp24.03.2017
    Illustrated instructions
      Instructions
      Up